Phase 1/2 Open-Label Study with Extended Follow-Up to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of ALN-6457 in Participants with Symptomatic Prion Disease
Prion diseases are rare conditions that damage the brain and nervous system. Currently, there are no cures and very few treatment options. This study is testing an experimental medicine called ALN-6457 in people experiencing symptoms of prion disease. It is an integrated Phase 1 and 2 trial, meaning this is the first time the drug is being given to humans. The main goal of the trial is safety. Doctors want to understand any side effects, find the right dose, and see how the body handles the medicine. They will also look at whether the treatment lowers proteins linked to nerve damage. Because this is an 'open-label' study, all participants will receive the active study drug rather than a dummy treatment (placebo). Taking part involves hospital visits, regular health checks, blood tests, and monitoring over an extended period.
A colpo d'occhio
Di cosa tratta questo studio?
Prion diseases are rare and serious illnesses that affect the brain and nervous system. They happen when normal proteins in the body fold into an abnormal shape, forming clumps that harm brain cells over time. Because these conditions progress quickly and currently have limited treatment choices, scientists are actively searching for new ways to protect the brain.
This clinical study is evaluating an experimental drug called ALN-6457 sodium. The medicine is designed to reduce the production of the abnormal prion protein in the body. By lowering these levels, researchers hope to slow down or prevent further harm to brain cells.
Because this is a 'first-in-human' Phase 1/2 trial, the primary focus is to find out if the drug is safe and tolerable. Doctors will closely watch for any side effects and see how the drug is absorbed and broken down. They will also test blood and spinal fluid for specific markers, such as 'neurofilament light chain' (a protein released when nerves are injured), to see if the drug shows early signs of protecting brain tissue.
Studies like this are an essential first step in medical research. While it is too early to know how effective the drug will be, the findings will provide vital clues about whether ALN-6457 could become a helpful treatment for prion disease in the future.
Punti chiave
- This is an early-stage trial testing the experimental drug ALN-6457 in humans for the first time.
- The study is designed for adults who are currently experiencing symptoms of prion disease.
- Every participant will receive the active study medicine; there is no dummy pill (placebo).
- Researchers will closely check safety, side effects, and markers of brain health.
- Taking part requires regular hospital visits, blood tests, and spinal fluid checks.
Chi può essere idoneo?
This trial is open to adults aged 18 and over who have been diagnosed with symptomatic prion disease. This means that a person must be showing active symptoms of the illness, rather than just carrying a genetic risk without symptoms.
Men and women of any background can take part, provided they meet the specific medical criteria set by the research team. These criteria usually require that a person is well enough to travel for study visits and undergo the necessary tests safely.
Certain medical conditions, treatments, or complications might mean someone cannot take part. The trial doctor will review each person's medical history, current medicines, and general health to confirm whether the study is a safe and suitable option for them.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- I am aged 18 years or older.
- I have been diagnosed with a prion disease (such as CJD).
- I am currently experiencing symptoms related to the disease.
- I am able and willing to attend regular hospital appointments for treatment and tests.
- I am comfortable undergoing procedures like blood tests and lumbar punctures.
Cosa comporta la partecipazione?
If you take part in this study, you will receive multiple doses of the trial medicine, ALN-6457. You will need to attend a specialist hospital or clinical trial centre for regular appointments. During these visits, doctors will perform physical examinations, check your vital signs, and carry out neurological checks to monitor your nervous system.
You will have regular blood tests to check your general health and measure drug levels. You will also have lumbar punctures (also known as spinal taps), which involve numbing the lower back with local anaesthetic to collect a small amount of fluid from around the spine. This fluid is tested to see how much medicine reaches the nervous system and whether prion protein levels are changing. The trial includes an extended follow-up period to monitor your safety and wellbeing over time.
Rischi e benefici potenziali
Luoghi (1)
- —Non verificatoBelgio
Domande comuni
Cosa significa 'a etichetta aperta'?
Open-label means that both you and your study doctors know you are receiving the real experimental medicine. There is no placebo (dummy medicine) used in this trial.
Is ALN-6457 a proven cure for prion disease?
No. It is an experimental drug in the earliest stages of human testing. The main purpose of this study is to find out if it is safe and what dose works best.
What is a lumbar puncture and will it hurt?
A lumbar puncture is a test where a thin needle is placed into the lower back to take a sample of spinal fluid. The area is numbed first with local anaesthetic to minimise discomfort, though some people feel mild pressure or get a mild headache afterwards.
Will taking part cost anything?
No, the trial medicine and all study-related medical tests are provided free of charge. Clinical trials often help cover travel and accommodation expenses for you and a carer.
Posso abbandonare lo studio se cambio idea?
Yes. You have the right to withdraw from the trial at any point, for any reason. Your regular NHS care and support will continue unchanged.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.